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Patients presented with atrial fibrillation (AF) are at increased risk of stroke, and prophylactic treatment with oral anti-
coagulants (OAC) is central to the management of this com-
mon arrhythmia.1 The increase in AF prevalence and change in 
guideline recommendations have increased the proportion of 
patients with AF at risk of bleeding related to OAC treatment.2,3 
The most feared bleeding complication related to OAC is intra-
cranial bleeding (including intracerebral hemorrhage), which is 
associated with a poor prognosis of functionality and a 30-day 
mortality up to 40%.4,5 OAC treatment will usually be discon-
tinued immediately in patients with OAC-related intracranial 
bleeding. If OAC is to be reintroduced in these clinically com-
plicated patients with AF, the risk of ischemic stroke should be 
balanced against the risk of recurrent intracranial bleeding.6
Previous observational studies have indicated a clinical 
benefit of resuming OAC treatment in patients with AF sus-
taining an intracerebral hemorrhage or a trauma-induced in-
tracranial bleeding.6–8 Common for these investigations was 
that the antithrombotic treatment options included vitamin K 
antagonists or antiplatelet therapy, and all showed lower risk 
of ischemic stroke if warfarin treatment was resumed.9
The landmark non–vitamin K antagonist OAC (NOAC) 
trials showed a clear benefit over warfarin in terms of lower 
risk for intracerebral hemorrhage.10 Nevertheless, a universal 
exclusion criteria for all 4 trials were patients with prior intra-
cranial hemorrhage (including both trauma-induced bleeding 
events and intracerebral hemorrhages).11–14 Thus, no evidence 
exists for whether the efficacy and safety for NOAC versus 
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warfarin are maintained in patients with AF sustaining an 
intracerebral hemorrhage. To guide clinical practice, we inves-
tigated the comparative effectiveness and safety of NOACs 
versus warfarin in patients with AF sustaining an intracerebral 
hemorrhage.
Methods
We conducted an observational cohort study using data from the na-
tionwide Danish registries including patients with AF sustaining an 
intracerebral hemorrhage with subsequent OAC treatment initiation. 
Because of the sensitive nature of the data collected for this study, 
requests to access the data set from qualified researchers trained in 
human subject confidentiality protocols may be sent to The Danish 
Health Data Agency at forskerservice@sundhedsdata.dk.
Sources of Data
Study data were obtained from 4 Danish nationwide databases using 
a unique identification number allowing linkage on individual level 
between databases. (1) We included data from the Danish Stroke 
Registry holding quality data on stroke patients since 2003 including 
data on type of stroke, stroke severity, smoking status, and alcohol 
consumption15; (2) the Danish National Prescription Registry hold-
ing information on purchase date, Anatomical Therapeutic Chemical 
classification code, and package size for every prescription claim 
since 199416; (3) the Danish Civil Registration System holding in-
formation on sex, date of birth, vital, and emigration status17; and 
(4) the Danish National Patient Register, which includes admission/
discharge date, and discharge International Classification of Diseases 
(ICD) diagnoses for hospital admissions since 1977.18
Study Population
Patients with an incident discharge diagnosis for primary spontaneous 
intracerebral hemorrhage registered in the Danish Stroke Registry 
were considered for inclusion. Because we focused on the compar-
ative effectiveness and safety of 2 different OAC treatments, patients 
were eligible for study inclusion when they claimed a prescription of 
warfarin or a NOAC agent (dabigatran, rivaroxaban, or apixaban) in 
the period from January 2003 to April 2017 (end of inclusion) after 
the index event. Edoxaban treatment was not considered because of 
late entry in the study period. The following Anatomical Therapeutic 
Chemical codes were used to define OAC treatment exposure status: 
B01AE07, BF01AF01, and BF01AF02 for NOACs and B01AA03 
for warfarin. We restricted the study to patients with a prior hospital 
diagnosis of AF at the time of OAC treatment initiation (index date) 
recorded in the Danish National Patient Registry or in the Danish 
Stroke Registry. This was done to ensure a strong indication for OAC 
treatment recommendation. Patients with hospital diagnoses indicat-
ing valvular AF, defined as mitral stenosis (ICD: I05) or mechanical 
heart valves (ICD: Z952, Z953, and Z954) at the time of an OAC 
prescription claim were excluded. Patients were followed from the 
date of an OAC prescription claim until June 30, 2017, in the Danish 
National Patient Registry. The 10th revision of ICD codes was used 
to identify outcomes and clinical characteristics. The Danish Health 
Data Authority provided the data material. No ethical approval was 
obtained, as this is not mandated for registry studies in Denmark.
Outcomes and Comorbidities
Information on outcomes was obtained from the Danish National 
Patient Registry. The primary effectiveness outcome was a hospital 
diagnosis of ischemic stroke (ICD: I63 and I64.9), and the primary 
safety outcome was a hospital diagnosis of recurrent intracerebral 
hemorrhage (ICD: I61). For study outcomes, we only included pri-
mary diagnosis codes and restricted to patients who were admitted 
to the hospital to increase the validity of the coded diagnosis. The 
coding validity of these outcomes has previously been validated in 
the Danish National Patient Registry with a positive predictive values 
of ≥80%.19,20
Index intracerebral hemorrhage severity was evaluated according to 
the Scandinavian Stroke Scale, which (among others) include assess-
ment of the patient’s level of consciousness, eye movements, coordi-
nation ability, and ability to speak.21 The total score of maximum 58 
(lower scores indicate more severe intracerebral hemorrhage events) 
was stratified as nonsevere 39 to 58, moderately severe 20 to 38, and se-
vere 0 to 19. Thromboembolic risk was quantified based on comorbidity 
information included in the CHA2DS2-VASc score.22 Concomitant car-
diovascular medication and comorbidities were also collected from 
the Danish Nationwide Patient Registry and the Danish Nationwide 
Prescription Registry (Table I in the online-only Data Supplement).
Statistics
Time-to-event data were used to analyze risk of outcomes asso-
ciated with treatment exposure groups. Time at risk was measured 
from the date of the initial OAC prescription until the outcome of 
interest, emigration, death, or end of study period, whichever came 
first. Outcomes were examined at 1 year of follow-up and 3 years 
follow-up period; the latter was selected to restrict follow-up time 
for warfarin users, which could not be achieved among NOAC users 
because of more recent market entry (August 2011).
To depict risk development over time in treatment groups, we cal-
culated the cumulative incidence of outcomes based on the Aalen-
Johansen estimator, to account for the competing risk of death.22 The 
pseudovalue approach was used to estimate the cumulative incidence 
at fixed time points with death considered as a competing event. The 
risks obtained from the pseudovalues were analyzed in a generalized 
linear model to estimate the relative risk in terms of risk ratios as 
well as absolute risk reduction.23,24 The latter measure was included 
to reflect the clinical impact of selecting either treatment approaches.
The analyses were conducted in agreement with the causal infer-
ence framework of potential outcomes. To allow for balanced com-
parison between treatment groups, propensity score methodology 
was applied to control for baseline confounding. We used an inverse 
probability of treatment weight and applied stabilized weights to bal-
ance covariate differences between exposure groups (see Methods in 
the online-only Data Supplement for details). The underlying pro-
pensity score was calculated as the probability for receiving either 
a NOAC or a warfarin treatment.25 The underlying logistic regres-
sion model to predict probability of treatment included the following 
covariates: sex, age (restricted cubic spline), stroke severity cate-
gory (measured according to the Scandinavian Stroke Scale), days 
since hospital discharge (restricted cubic spline), length of hospital 
stay for the index intracerebral hemorrhage event (restricted cubic 
spline), reduced renal function, alcohol consumption, smoking status, 
CHA2DS2-VASc score (categorical), and aspirin treatment.
To allow for an evaluation of treatment effectiveness and safety in 
different clinical scenarios, we conducted a stratified analysis based 
on the severity of the index event grouped as nonsevere and moder-
ately to severe intracerebral hemorrhages.
Sensitivity Analyses
We conducted 3 sensitivity analyses to assess the robustness of our 
methodological approach, and to evaluate the internal validity of the 
observed associations.
First, the study population was restricted to patients who claimed 
an OAC prescription within the first year after hospital discharge fol-
lowing the index intracerebral hemorrhage event. Second, to inves-
tigate the presence of residual confounding, we conducted analyses 
using falsification outcomes, that is, outcomes that were unlikely 
to be causally associated to the treatment exposure.26 For this anal-
ysis, we used hospital diagnosis of pneumonia (ICD: J12 J13 J14 
J15 J16 J17 J18 A481 A709) as falsification outcome); and urinary 
tract infections ascertained by a prescription claim for trimethoprim 
(J01EA01), pivmecillinam (J01CA08), sulfamethizole (J01EB02), 
or nitrofurantoin (J01XE01), which are used specifically for urinary 
tract treatment in Denmark.27 Last, we restricted the patient inclusion 
period by exclusion of patients enrolled before year 2011 (first year 
of NOAC market availability in Denmark).
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Stata/MP, version 15 (StataCorp) and R version 3.1.1 (The R 
Foundation) were used for the statistical analysis. A P value <0.05 
was considered statistically significant.
Results
From a population of 9846 patients with incident intracerebral 
hemorrhage between January 2003 and April 2017, we identi-
fied 1864 AF patients discharged from the hospital with an 
intracerebral hemorrhage. A total of 274 patients initiated war-
farin treatment, whereas 348 initiated NOAC treatment, which 
comprised the study population (Figure 1). The mean age was 
77.4 years for NOAC-treated patients (43% females) and 74.6 
years for warfarin-treated patients (34% females). The mean 
Scandinavian Stroke Scale severity score was 42.2 and similar 
between treatment groups. The proportion of patients with se-
vere intracerebral hemorrhage was marginally higher among 
NOAC users (12.4% versus 8.4%), whereas the proportion of 
nonsevere was higher among warfarin users (69.5% among 
NOAC users versus 74.8% among warfarin users; Table 1). 
The overall proportion of patients with prior thromboembo-
lism was 52%, and 62% of the patients were hypertensive. The 
mean CHA2DS2-VASc score was 4.4 (SD=1.7) and similar in 
both treatment groups.
The population for creating a model for the propensity 
score was based on 477 patients (Figure 1). Graphical inspec-
tion of the propensity score distribution for NOAC users and 
warfarin users revealed sufficient overlap between treatment 
groups; no extreme values were observed (Figure I in the 
online-only Data Supplement).
Risks for Ischemic Stroke
During 1 year of follow-up, a total of 36 ischemic stroke events 
were observed (Table 2), 21 for warfarin-treated patients and 
15 for NOAC-treated patients. Inverse probability weighted 
cumulative incidence curves indicated a difference in risk over 
time with warfarin being associated with a higher risk in com-
parison with NOAC-treated patients (Figure 2). The 1-year is-
chemic stroke risk for warfarin was 7.85% versus 4.01% for 
NOAC-treated patients, with an absolute weighted risk reduc-
tion of 3.78% (95% CI, −0.15% to 7.71%). The corresponding 
risk ratio indicated nonsignificantly lower risk among NOAC 
users: 0.52 (95% CI, 0.27–1.00; Figure 3). The absolute risk 
reduction and risk ratio were slightly attenuated when using 
3-year follow-up time, but the direction of the results was 
maintained (Figure II in the online-only Data Supplement).
Restricting the analysis to patients who received OAC 
treatment within 1 year after hospital discharge reduced the 
study population to 179 warfarin-treated patients and 205 
NOAC-treated patients. The 1-year risk reduction was 3.89% 
(95% CI, −1.34% to 9.13%), and the corresponding risk ratio 
was 0.54 (95% CI, 0.12–2.43); both results were in accord-
ance with the main analysis but with wider CIs because of a 
lower sample size.
Risks for Recurrent Intracerebral Hemorrhage
Nineteen intracerebral hemorrhages were observed among 
warfarin users and 18 among NOAC users during 1 year of 
follow-up. Risk development during this period indicated a 
marginally higher risk associated with warfarin treatment 
compared with NOAC treatment during the first 3 months 
(Figure 2). The inverse probability weighted 1-year intrace-
rebral hemorrhage risk was 7.00% for warfarin, and 5.07% 
for NOAC; the absolute weighted risk reduction was 1.93% 
(95% CI, −2.02% to 5.87%; Table 2). The corresponding risk 
ratio was statistically nonsignificantly different 0.72 (95% CI, 
0.38–1.38; Figure 3). Using 3-year follow-up time attenuated 
the difference in risk of recurrence (Figure 2): the risk reduc-
tion was 0.51% (95% CI, −3.77% to 4.78%), and the risk ratio 
was 0.94 (95% CI, 0.53–1.64).
When restricting the study population to patients who re-
ceived OAC treatment within 1 year after hospital discharge 
(sensitivity analysis), the 1-year risk reduction of recurrence 
was 0.97% (95% CI, −4.01% to 5.95%), and the adjusted risk 
ratio was 1.07 (95% CI, 0.39–2.95).
Intracerebral Hemorrhage Severity
A total of 447 patients were classified as having a nonsevere 
intracerebral hemorrhage and 175 patients survived a mod-
erate to severe (Scandinavian Stroke Scale ≤38) intracerebral 
hemorrhage. In the former group, we observed 23 ischemic 
stroke events and 24 recurrent intracerebral hemorrhages, 
whereas in patients with moderate to severe index event, we 
observed 13 ischemic strokes and 16 intracerebral hemor-
rhages —using 1 year of follow-up data.
The risk reduction for ischemic stroke among nonse-
vere patients was 2.08% (95% CI, −2.03% to 6.18%), and 
the risk ratio was 0.67 (95% CI, 0.29–1.51; Figure 3). For 
intracerebral hemorrhage, the risk reduction and risk ratio 
were 4.31% (95% CI, −0.03% to 8.95%) and 0.49 (95% CI, 
0.21–1.11), respectively.
Among patients classified with moderate to severe intra-
cerebral hemorrhage, the absolute risk reduction for ischemic 
Intracerebral hemorrhagic patients
N = 9,846
Not diagnosed 
with AF
N = 7,899
Valvular AF
N = 83
AF patients sustaining an
intracerebral hemorrhagic 
N = 1,864
Study population N = 622
Subgroup for propensity model:
Warfarin users, N = 131 NOAC 
users, N = 346
Not receiving OAC
treatment N = 1,242
Figure 1. Flowchart of the study population. The subgroup of 477 patients 
was used to obtain the model for the propensity score (inclusion from Au-
gust 2011 through April 2017). AF indicates atrial fibrillation; NOAC, non–
vitamin K antagonist OAC; and OAC, oral anticoagulant.
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stroke was 7.77% (95% CI, −1.23% to 16.77%), and the risk 
ratio was 0.53 (95% CI, 0.24–1.18; Figure 3). The risk reduc-
tion for recurrent intracerebral hemorrhage was −3.86% (95% 
CI, −11.18% to 4.00%) indicating lower risk among warfarin 
users compared with NOAC users. The corresponding risk 
ratio was 1.20 (95% CI, 0.78–1.84). Caution is warranted in 
interpretation of the subgroup results of moderate to severe 
index event, as the propensity score distribution did not indi-
cate sufficient overlap between the 2 treatment options (Figure 
III in the online-only Data Supplement).
Sensitivity Analyses
Examining the treatment-associated falsification outcomes 
revealed nonsignificant adjusted risk ratios of 1.07 (95% CI, 
0.67–1.72) for pneumonia and 1.13 (95% CI, 0.87–1.48) for 
urinary tract infection treatment when comparing NOAC 
treatment versus warfarin. The results from the falsification 
analyses may indicate low risk of residual confounding in the 
main analysis.
Restricting the patient population by only including 
patients diagnosed after August 11, 2011, restricted the patient 
Table 1. Patient Characteristics
Characteristics, % (N) Warfarin NOAC All Absolute Standardized Difference
N 274 348* 622 Before IPT weighting After IPT weighting
Females† 34.3 (94) 42.8 (149) 39.1 (243) 0.18 0.01
Age, mean (SD)† 74.6 (9.3) 77.4 (9.0) 76.1 (9.2) 0.31 0.01
Prior OAC treatment†‡ 45.6 (125) 44.8 (156) 45.2 (281) 0.02 <0.01
Days since intracerebral hemorrhage 
diagnosis,§ mean (SD)†
109.1 (72.4) 110.1 (74.6) 109.6 (73.6) 0.01 0.04
Scandinavian Stroke Severity scale†
  Mean score (SD) 43.0 (14.3) 41.6 (15.4) 42.2 (14.9) 0.09 0.02
  39–58 (nonsevere) 74.8 (205) 69.5 (242) 71.9 (447) 0.12 0.01
  20–38 (moderately severe) 16.8 (46) 18.1 (63) 17.5 (109) 0.03 0.01
  0–19 (severe) 8.4 (23) 12.4 (43) 10.6 (66) 0.13 0.03
Mean days hospitalized from index 
event (SD)†
28.7 (13.2) 29.0 (19.4) 28.9 (17.0) 0.01 0.04
Smoking status†
  Smoker 16.1 (44) 13.8 (48) 14.8 (92) 0.06 <0.01
  Former smoker 30.7 (84) 31.0 (108) 30.9 (192) 0.01 <0.01
  Never smoker 34.3 (94) 36.8 (128) 35.7 (222) 0.05 <0.01
  Smoking not recorded 19.0 (52) 18.4 (64) 18.6 (116) 0.02 <0.01
Hypertension† 58.8 (161) 64.7 (225) 62.1 (386) 0.12 <0.01
Prior thromboembolism† 55.1 (151) 48.9 (170) 51.6 (321) 0.13 <0.01
Diabetes mellitus† 16.8 (46) 17.2 (60) 17.0 (106) 0.01 0.01
Congestive heart failure† 35.8 (98) 30.2 (105) 32.6 (203) 0.12 <0.01
Vascular disease† 25.5 (70) 18.4 (64) 21.5 (134) 0.18 <0.01
CHA
2
DS
2
-VASc score, mean (SD) 4.4 (1.7) 4.3 (1.6) 4.4 (1.7) 0.02 <0.01
COPD 16.4 (45) 17.5 (61) 17.0 (106) 0.03 0.04
Myocardial infarction 11.7 (32) 11.5 (40) 11.6 (72) 0.01 0.12
Cancer 14.6 (40) 22.4 (78) 19.0 (118) 0.20 0.14
Alcohol usage status†
  Consumer 73.7 (202) 77.3 (269) 75.7 (471) 0.08 <0.01
  Heavy consumption 10.6 (29) 8.6 (30) 9.5 (59) 0.07 <0.01
  Usage not registered 15.7 (43) 14.1 (49) 14.8 (92) 0.05 <0.01
Renal dysfunction 14.2 (39) 9.2 (32) 11.4 (71) 0.16 0.01
COPD indicates chronic obstructive pulmonary disease; IPT, inverse probability treatment; IQR, interquartile range; NOAC, non–vitamin K antagonist 
OAC; and OAC, oral anticoagulant.
*Rivaroxaban, 88; apixaban, 159; and dabigatran, 101.
†Included in adjustment model.
‡Prescription claim up to 365 days before the index event; n=31 patients shifted treatment.
§Days counted from index event to first prescription claim of an OAC drug.
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population to 497 patients (see Table II in the online-only Data 
Supplement for patient characteristics before and after the 
NOAC marked availability). The 1-year risk ratio for ischemic 
stroke was 0.74 (95% CI, 0.30–1.84), for intracerebral hemor-
rhage the risk ratio was 0.52 (95% CI, 0.26–1.05).
Discussion
This is the first nationwide cohort study to compare the effec-
tiveness and safety of NOAC versus warfarin among patients 
with AF sustaining an intracerebral hemorrhage. Our principal 
finding was that NOAC treatment was associated with a lower 
risk of ischemic stroke in comparison with warfarin, although 
the adjusted risk ratio did not reach statistical significance. 
Second, we observed a nonsignificant different risk ratio of 
recurrent intracerebral hemorrhage among NOAC-treated 
patients in comparison with warfarin. The risk differences 
indicated that NOAC treatment was associated with >3 per-
centage point lower 1-year risks of both ischemic stroke and 
intracerebral hemorrhage compared with warfarin.
Patients with AF and concomitant intracerebral hemor-
rhage poses a clinical conundrum, and guideline recommen-
dations have been lacking to guide treating physicians. The 
patient will often be considered at high stroke risk (from 
comorbidities associated with stroke in AF), whereas the 
bleeding event may be the primary concern for both the patient 
and the healthcare providers. Thus, the latent ischemic stroke 
risk might be of less concern, albeit this should still be among 
the primary concerns in the management of AF. Previous 
Table 2. Event Count and Inverse Probability Treatment Weighted Absolute Risks for Investigated Outcomes According to Treatment Status at 1 
Year and 3 Years of Follow-Up
Warfarin NOAC Weighted Risk Difference*
One-year follow-up
  Ischemic stroke
   Events 21 15  
   Absolute risk (95% CI) 7.85% (4.50% to 11.20%) 4.01% (2.02% to 6.14%) 3.78% (−0.15% to 7.71%)
  Recurrent intracerebral hemorrhage
   Events 19 18  
   Absolute risk (95% CI) 7.00% (3.83% to 10.17%) 5.07% (2.74% to 7.41%) 1.93% (−2.02% to 5.87%)
Three-year follow-up
  Ischemic stroke
   Events 32 29  
   Absolute risk (95% CI) 11.56% (7.64% to 15.47%) 8.83% (5.32% to 11.23%) 3.28% (−1.60% to 8.20%)
  Recurrent intracerebral hemorrhage
   Events 22 27  
   Absolute risk (95% CI) 7.85% (4.56% to 11.15%) 7.35% (4.61% to 10.07%) 0.51% (−3.77% to 4.78%)
NOAC indicates non–vitamin K antagonist oral anticoagulant.
*Warfarin used as a reference.
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Figure 2. Inverse probability treatment weighted 
cumulative incidence of ischemic stroke and 
intracerebral hemorrhage for warfarin and non–
vitamin K antagonist oral anticoagulant (NOAC) 
treatments.
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research in this field has focused on resuming treatment with 
vitamin K antagonists and have indicated that warfarin treat-
ment may be a safe option.6,7,9,28 The landmark NOAC trials 
excluded all patients with previous intracranial hemorrhage, 
but reported a class effect of the drugs in reducing the risk of 
intracranial hemorrhage in comparison with warfarin. Study-
level meta-analysis showed a relative risk reduction in intra-
cerebral hemorrhage of 0.49 (95% CI, 0.38–64).10 Although 
this result is generalizable to a broad AF population, it has 
not been established whether this risk reduction would be 
achieved in an AF population with intracerebral hemorrhage. 
In this observational study including data reflecting clinical 
practice, we obtained a similar relative risk estimate for intra-
cerebral hemorrhage when contrasting NOACs versus war-
farin. Moreover, our results also suggest a clear trend of an 
appealing effectiveness profile for NOACs in comparison with 
warfarin in this population. Although this could be connected 
to differences in drug effects, perhaps a more plausible expla-
nation would be because of dose management of the selected 
drugs. With the NOAC agents, the treating physician does not 
have dose titration options, because these are provided in fixed 
dosages (standard dose or reduced dose, administrated mainly 
dependent on renal function).
The mechanism for lower risk of intracerebral hemorrhage 
with NOAC treatment compared to warfarin is not fully un-
derstood. One possible explanation relates to how warfarin 
affects the coagulation system, which among others includes 
inhibition of activated tissue factor (factor VIIa). The cere-
bral blood vessels contain high concentrations of factor VII 
and promote coagulation in the event of endothelia disruption 
with bleeding into the brain wall.29 Although this may explain 
improved prognosis for NOAC patients experiencing an in-
tracranial hemorrhage in contrast to warfarin patients,30 it re-
mains unsure if this mechanism may also in part explain our 
observations of a better safety profile in terms of recurrent 
intracerebral hemorrhage. Currently, randomized controlled 
trials and prospective cohort studies are either in preparation 
or ongoing to investigate the efficacy of specific NOAC agents 
versus warfarin, antiplatelet therapy, or no treatment.31–33
Selecting the optimal timing for resuming (or initiating) 
OAC treatment post an intracerebral hemorrhage event in AF 
is debatable. Contemporary guidelines suggest reinitiating of 
OAC after 4 to 8 weeks (Class IIb) provided that the bleeding 
cause and risk factors are controlled.3 In our study, observa-
tion time commenced at the first OAC prescription claim post 
the index event of intracerebral hemorrhage. As we included 
prevalent OAC users, we could not assess the exact date of 
OAC treatment initiation. To guide optimal timing of OAC 
initiation after an intracerebral hemorrhage would require 
carefully conducted randomized controlled trials, and obser-
vational data may have a high risk of bias by indication.34
Limitations
The nature of this study was observational, and the data 
applied was collected for administrative purposes—both must 
be considered in interpretation of the results. Residual or 
unmeasured confounding is likely to persist and may partly 
explain the observed associations. Additionally, treatment 
strategies have evolved during the applied study period, in-
cluding statin use and blood pressure control, which we could 
not investigate because of the size of the study population. We 
lacked imaging information and could not assess the volume 
and location of the hematoma. Hence, we cannot rule out the 
influence of the underlying cerebral small vessel diseases that 
could cause the hemorrhage itself, therefore also the possible 
risk of recurrence. Indeed, lobar versus nonlobar bleeding 
have been shown to carry high prognostic value in terms of 
bleeding recurrence. We also lacked information on intensity 
Figure 3. Forest plot of inverse probability treatment weighted risk ratios contrasting non–vitamin K antagonist oral anticoagulants (NOACs) vs warfarin (ref-
erence) and associated outcomes under different analytic approaches.
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and quality of warfarin treatment. Indeed, the higher risk of is-
chemic stroke among warfarin users could indicate dose titra-
tion to a lower threshold than usually suggests (international 
normalized ratio between 2 and 3).
The falsification end point analysis did not indicate that 
confounding was the primary explanation of the results. 
Indication bias might also be present and may have influ-
enced the selection of treatment strategy and choice of agent. 
However, the distributions of the propensity for receiving ei-
ther NOAC or warfarin were very similar, indicating that our 
modeling strategy sufficiently controlled for baseline con-
founding (including indication bias assuming correct model 
specifications) to allow for causal inference of the obtained 
associations. We could not assess risk differences within the 
NOAC agents due, and low sample size, in general, preclude 
firm conclusions based on these data.
We did not restrict our main analysis to patients who com-
menced OAC treatment within a certain time after the index 
intracerebral hemorrhage event, but investigated this in a sen-
sitivity analysis. Although this information was included in 
the underlying propensity model, time since stroke is likely 
a strong predictor of time to recurrence and warrants further 
investigations.35,36
Our results may potentially not be generalizable to the 
general AF population who sustain an intracerebral hemor-
rhage as we focused on NOACs versus warfarin among those 
who were selected to resume OAC treatment. Among those 
patients where OAC treatment has been deemed suitable, a 
NOAC agent seems preferable over warfarin.
Conclusions
In this Danish nationwide observational cohort study of 
patients with AF sustaining an intracerebral hemorrhage, 
NOAC treatment was associated with a lower risk of is-
chemic stroke and intracerebral hemorrhage in comparison 
with warfarin treatment, but low sample size prevented from 
statistically significant conclusions. Our results add to the 
current recommendation for selecting a NOAC agent as the 
preferred stroke prophylaxis in this subgroup of patients with 
AF when suitable.
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